Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.0868
Abstract: This comparative effectiveness research study examines the effectiveness of full vaccination with Ad26.COV2.S vs BNT162b2 against COVID-19–related hospitalization. read more here.
Keywords: bnt162b2; ad26 cov2; covid; vaccine ... See more keywords
Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.26335
Abstract: Key Points Question What is the durability of humoral and cellular immune responses in individuals who originally received the BNT162b2 vaccine and were boosted with Ad26.COV2.S or BNT162b2? Findings In this cohort study of 68… read more here.
Keywords: durability heterologous; durability; homologous covid; ad26 cov2 ... See more keywords
Persistence of Ad26.COV2.S-associated VITT and specific detection of VITT antibodies.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of hematology"
DOI: 10.1002/ajh.26488
Abstract: Rare cases of COVID-19 vaccinated individuals develop anti-platelet factor 4 (PF4) antibodies that cause thrombocytopenia and thrombotic complications, a syndrome referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT). Currently, information on the characteristics and persistence… read more here.
Keywords: cov2; cov2 associated; associated vitt; ad26 cov2 ... See more keywords
Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccines
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28032
Abstract: SARS‐CoV‐2 vaccines have contributed to the control of COVID‐19 in some parts of the world. However, the constant emergence of variants of concern (VOCs) challenges the effectiveness of SARS‐CoV‐2 vaccines over time. In particular, Omicron… read more here.
Keywords: mrna 1273; neutralizing antibodies; bnt162b2; ad26 cov2 ... See more keywords
Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Emergency Medicine"
DOI: 10.1016/j.annemergmed.2021.04.035
Abstract: Vaccine-induced thrombotic thrombocytopenia is a newly described disease process in the setting of expanding access to COVID-19 vaccination. The United States Centers for Disease Control and Prevention recommends treatment with an alternative to heparin in… read more here.
Keywords: thrombocytopenia; ad26 cov2; vaccine induced; vaccination ... See more keywords
Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination
Sign Up to like & getrecommendations! Published in 2021 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2021.07.002
Abstract: CSVV: cutaneous small vessel vasculitis INTRODUCTION Two single-dose COVID-19 vaccines utilizing the adenoviral vector platform, ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Janssen), have recently been associated with rare immune-mediated thrombotic events and thrombocytopenia. In response to… read more here.
Keywords: ad26 cov2; vessel vasculitis; small vessel; cov2 ... See more keywords
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
Sign Up to like & getrecommendations! Published in 2021 at "NPJ Vaccines"
DOI: 10.1038/s41541-021-00301-y
Abstract: Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2… read more here.
Keywords: ad26 cov2; respiratory disease; vaccine; sars cov ... See more keywords
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Sign Up to like & getrecommendations! Published in 2021 at "Nature"
DOI: 10.1038/s41586-021-03681-2
Abstract: The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern… read more here.
Keywords: wa1 2020; ad26 cov2; antibody; cov variants ... See more keywords
Relative effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines and homologous boosting in preventing COVID-19 in adults in the US
Sign Up to like & getrecommendations! Published in 2023 at "Open Forum Infectious Diseases"
DOI: 10.1101/2023.02.10.23285603
Abstract: Background: Few head-to-head comparisons have been performed on the real-world effectiveness of COVID-19 booster vaccines. We evaluated the relative effectiveness (rVE) of a primary series of mRNA-1273 versus BNT162b2 and Ad26.COV2.S and a homologous mRNA… read more here.
Keywords: mrna 1273; mrna; bnt162b2; covid ... See more keywords
Atypical presentation of Sweet syndrome with nodular erythema and oral ulcerations provoked by Ad26.COV2.S SARS‐CoV‐2 vaccination and review of literature
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15923
Abstract: The aim of this article is to present the case of acute febrile neutrophilic dermatosis (Sweet syndrome—SS) after Ad26.COV2.S vaccination against SARS‐CoV‐2. To the best of our knowledge, this is the second case of SS… read more here.
Keywords: sweet syndrome; nodular erythema; ad26 cov2; oral ulcerations ... See more keywords
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine
Sign Up to like & getrecommendations! Published in 2022 at "Immunological Reviews"
DOI: 10.1111/imr.13088
Abstract: Since its emergence in late 2019, the coronavirus disease 2019 (COVID‐19) pandemic has caused substantial morbidity and mortality. Despite the availability of efficacious vaccines, new variants with reduced sensitivity to vaccine‐induced protection are a troubling… read more here.
Keywords: efficacy ad26; ad26 cov2; vaccine; immunogenicity efficacy ... See more keywords